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sion-free survival (PFS), on the cohort of 2000 patients with Her2 Ne mBC negative
and a subanalysis of the populations of patients with triple negative of patients
with Her2 Neu Negative, taking into account direct medical costs and social costs
due to premature death, in a horizon of 5 years (discount rate 5%). RESULTS: The
40.35% of patients survived after 12 months using bevacizumab paclitaxel, while
only 35.20% did so with only administered paclitaxel. 59.6% of these patients were
PFS with combination therapy, while 37.71% did with monotherapy. Combined
therapy provides more effectiveness than monotherapy in terms of overall sur-
vival, progression-free survival (PFS) and therapeutic response. The incremental
cost of bevacizumab  paclitaxel is $9,639 USD obeying the PFS difference in time
between the two cohorts, and higher consumption on the combination versus
monotherapy. For triple negative subpopulation, the ICER is $2295 USD while for
the sub-population of HER 2 is $1854 USD. The ICER is compared against a threshold
of 3 times GDP per capita in Mexico. The ICER is lower than the threshold, so it is
cost-effective CONCLUSIONS: The combination of bevacizumab  paclitaxel, for
all cases studied, represents a better alternative cost effective versus paclitaxel
monotherapy.
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OBJECTIVES: : One-year adjuvant trastuzumab therapy increases disease-free and
overall survival in the adjuvant treatment of early HER2-positive breast cancer.
This study aims to assess the long-term cost-effectiveness of adjuvant trastu-
zumab treatment in Colombia METHODS: A Markov health-state transition model
was constructed to simulate the natural development of breast cancer in women
with HER2/neu-positive after 12 months of after trastuzumab adjuvant chemother-
apy over a lifetime perspective with annual transition cycles. The model incorpo-
rated five broad health states (disease-free, local recurrence [LCR], distant recur-
rence [DCR], cardiac failure, death). Baseline event rates and 3-year relative risk
(RR 0.75) were derived from the HERA trial. Costs and utility weights were from
the literature and were discounted by 3% annually RESULTS: On the basis of HERA
data, the model results showed that the utilization of adjuvant trastuzumab treat-
ment in early breast cancer can prolong 8.23 quality-adjusted life-years, compared
with 7, 78 quality-adjusted life-years in the standard chemotherapy group. The
incremental cost-effectiveness ratio was US$134,581. Results are moderately sen-
sitive to variation of relative risk, cost and number of cycles of trastuzumab and
less sensitive to breast cancer survival rates and variations in cardiac toxicity
CONCLUSIONS: The results suggest that the 1-year adjuvant trastuzumab treat-
ment is not cost-effective in Colombia. Both clinical and economic benefits were
not superior for the 1-year adjuvant trastuzumab treatment group compared with
the standard adjuvant chemotherapy group
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OBJECTIVES: To investigate the cost-effectiveness of the addition of trastuzumab
in a docetaxel monotherapy for women with HER2 metastatic breast cancer
(MBC) in the Greek healthcare setting.METHODS:A 3-state model was constructed
to simulate progression of the disease and overall quality adjusted survival for
patients receiving trastuzumab and docetaxel (TD) or docetaxel alone (D). The
model ran on 1-month cycles and simulated the progress of patients over a total
period of 12 years. Data on effectiveness were derived from a randomized con-
trolled trial comparing the outcomes of six cycles of docetaxel 100 mg/m2 every 3
weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg
weekly until disease progression in women with an average age of 53 years, and an
average body surface area of 1.7148m2. Costs were estimated from a third-party
payer perspective (2011 Euros), discounted at 3%/annum. RESULTS: Patients in the
TD arm had a mean incremental gain of 0.729 years (95% CI: 0.10, 1.36) in overall
survival and 0.449 (95% CI: 0.14 0.76) QALYs in quality-adjusted survival than those
in the D arm (1.992 vs. 1.542). Taking into account the average incremental cost of
30,474.62€ (95% CI: 23,592.04, 38,195.93) in the TD arm, the analysis reveals that
the Incremental Cost Effectiveness Ratios (ICERs) are estimated at 41,811.13€ and
67,824.92 for every life year or QALY, respectively, gained with trastuzumab. The
probabilistic sensitivity analysis showed that the ICERs produced by TD were
favourable at 17.1% of the Monte Carlo simulations at the 50,000€ and 35.7% at the
60,000€ threshold. CONCLUSIONS: The addition of trastuzumab to a first line treat-
ment of HER2 MBC with docetaxel represents an intervention with a high prob-
ability of being cost-effective from a third party-payer perspective
PCN83
COST-EFFECTIVENESS ANALYSIS OF COMBINATION THERAPIES INCLUDING
CLASS II ANTICANCER DRUG FOR ADVANCED OR METASTATIC GASTRIC
CANCER
Oh JY1, Lee EK2
1Sookmyung Women’s University, Seoul , South Korea, 2Sookmyung Women’s University, Seoul,
South Korea
OBJECTIVES: This study was performed to evaluate the cost-effectiveness of three
kinds of combination therapies including class II anti-cancer drugs in patients with
advanced or metastatic gastric cancer. METHODS: A Markov model was simulated
to assess the clinical and economic impact over 5 years from societal perspective.
Life Years Gained(LYG) were measured as a clinical outcome. In the model,
Docetaxelcisplatin5-FU(DCF), S-1cisplatin(SP), Capecitabinecisplatin(XP)
were selected as 1st line chemotherapies. When the disease progressed in the
second line therapy, Leucovorin 5-FU Irinotecan (FOLFIRI), it was assumed that
best supportive care was performed. Transition probabilities and mortality were
calculated by using adjusted parameter of “time to progression(TTP) or progression
free survival(PFS), overall survival(OS)”, which were obtained by indirect compar-
ison (control group: 5-FU  Cisplatin). Both direct medical costs and direct non-
medical costs were calculated. Costs and outcomes were discounted at an annual
rate of 5% and sensitivity analysis was performed to evaluate uncertainty in the
results. RESULTS: SP was dominated by XP because the total LYG per patient was
higher and cost was lower for XP compared with SP. When DCF was compared with
XP, incremental LYG was 0.045. However, incremental cost of DCF was also
10,719,975 KRW. Incremental cost-effectiveness ratio for DCF compared to XP was
calculated over 200 million per LYG. The results of the sensitivity analysis showed
no significant difference. CONCLUSIONS: Although a threshold of ICER is not fixed
in Korea, GDP per capita is usually used for reference. In that case, it is considered
that XP is cost-effective compared with DCF. Therefore, XP is the more cost-effec-
tive than DCF and SP. Further research should be carried out about cost-utility by
using utility weight according to the state of gastric cancer.
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OBJECTIVES: The incidence of cervical cancer in Spain is about 10/100,000 women
per year, one of the lowest in Europe. Screening programs and the population
vaccination against HPV are the two health care interventions aiming to reduce
cancer development.The objective of this study is to analyse the efficiency of the
population vaccination program in Spanish girls aged 11-14. METHODS: A simula-
tion discrete event model with a horizon of 20 years, under the perspective of the
National Health System, applied to the context of a high level of coverage Spanish
region (La Rioja) was developed. The cytological results of the population screening
program (14,760 women) and a review of literature on Spanish papers as well as
official statistics were used in the model. Finally, the model took also into account
the impact of some progression co-factors and the decrease on the immunity along
time. RESULTS: According to the model outputs, from the 2725 girls of the first
vaccination camping, 38.2% will not get infected by the HPV, 56.1% will clear the
virus in a spontaneous way, 3.8% will either not progress or do not confirm the
diagnoses, and, consequently, 1.9% would confirm a cervical lesion (29 LSIL and 23
HSIL), without considering the vaccination effect.A population vaccination pro-
gram (that reached a 97.5% coverage) vs no vaccination at all will have an Incre-
mental Cost Effectiveness Ratio of 43,657.8 euros per avoided pre-cancer cervical
lesion. CONCLUSIONS: Although some primary preventative measures are conve-
nient from a public health perspective, their final health and economic outcomes
should be analysed. According to the results of this study, targeting only some risk
populations should be considered as a way of increasing the low efficiency of the
general population vaccination program.
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OBJECTIVES: To analyze cost-effectiveness of a human papillomavirus (HPV) vac-
cination of boys at age 12 against oropharyngeal carcinoma and anogenital warts.
METHODS:We developed Markov decision model for a population of boys of age 12.
We assessed the following outcomes: costs, gains in quality adjusted life years
(QALYs), incremental cost-effectiveness ratio (ICER) for two options: vaccination
with quadrivalent vaccine and no vaccination, and for the two currently-available
vaccination choices: one with quadrivalent vaccine and one with bivalent vaccine.
We employed Monte Carlo microsimulation in the analysis of results. RESULTS:
Comparison of HPV vaccination of boys at age 12 vs. no vaccination resulted in ICER
of 109,384 GBP per QALY. The outcome was sensitive to the vaccination costs, the
probability of developing oropharyngeal carcinoma and anogenital warts, and pro-
portion of oropharyngeal carcinoma attributable to infection with types HPV-16
and HPV-18. When comparing quadrivalent and bivalent vaccines, resulting ICER
was 5,205 GPB per QALY. CONCLUSIONS:Our results indicate that HPV vaccination
of boys with quadrivalent vaccine is at present deemed not cost-effective, i.e., ICER
exceeds willingness-to-pay threshold of 30,000 GBP per QALY. Comparison of
quadrivalent and bivalent vaccines revealed that the additional benefits of protec-
tion against anogenital warts would favour quadrivalent vaccine as the vaccination
choice. An increase in incidence of HPV-positive oropharyngeal carcinoma and
anogenital warts, and reduction of vaccination costs could substantially reduce
ICER. Results of our study have potential healthcare policy implications for HPV
national immunisation programs in the UK and other jurisdictions of developed
countries.
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